AssociationBetween BRAF V 600 EMutationand MortalityinPatientsWithPapillaryThyroidCancer
暂无分享,去创建一个
Neill | P. Ladenson | D. Clark | D. Sidransky | J. Fagin | L. Yip | F. Vianello | C. Mian | M. Xing | E. Puxeddu | K. Carson | P. Santisteban | B. Jarzab | R. Tuttle | R. Elisei | L. Fugazzola | R. Tufano | R. Clifton-Bligh | M. Sywak | A. Alzahrani | A. Lam | A. Czarniecka | E. Robenshtok | B. Bendlova | D. Viola | G. Riesco-Eizaguirre | H. Nakayama | V. Sykorova | O. ChristineJ. | I. Pai | H. Westra
[1] A. Pinchera,et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.
[2] Rebeccah L. Brown,et al. Thyroid Cancer: Burden of Illness and Management of Disease , 2011, Journal of Cancer.
[3] P. Gattuso,et al. Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .
[4] V. Trovisco,et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.
[5] M. Ladanyi,et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.
[6] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[7] M. Xing,et al. BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.
[8] M. A. García-Cabezas,et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.
[9] M. Xing,et al. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.
[10] C. Nucera,et al. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. , 2011, Cancer research.
[11] M. Nikiforova,et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. , 2009, Surgery.
[12] H. Namba,et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.
[13] M. Xing,et al. Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.
[14] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[15] P. Hou,et al. The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells , 2012, Cell cycle.
[16] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[17] M. Xing,et al. Prognostic utility of BRAF mutation in papillary thyroid cancer , 2010, Molecular and Cellular Endocrinology.
[18] P. Ladenson,et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.
[19] Dagmara Rusinek,et al. Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. , 2010, Endokrynologia Polska.
[20] P. Ladenson,et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Hou,et al. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. , 2011, Endocrine-related cancer.
[22] R. Kodet,et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic , 2010, Journal of endocrinological investigation.
[23] N. Wada,et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. , 2007, Anticancer research.
[24] A. Toniato,et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience , 2011, Clinical chemistry and laboratory medicine.
[25] Louise Davies,et al. Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.
[26] P. Beck‐Peccoz,et al. BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.
[27] Y. Youn,et al. The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer , 2012, Cancer.
[28] Shinichi Suzuki,et al. BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.
[29] A. Pinchera,et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.
[30] S Lemeshow,et al. Confidence interval estimation of interaction. , 1992, Epidemiology.
[31] Robert A. Smith,et al. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. , 2011, Human pathology.
[32] A. Chou,et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. , 2010, Surgery.
[33] A. Abdel‐Mageed,et al. BRAF mutation in papillary thyroid carcinoma. , 2012, International journal of clinical and experimental medicine.